This article first appeared on GuruFocus .
-
Cash Balance:$17.1 million as of June 30, 2026.
-
Cash Operating Expenses:$3.9 million for Q2 2026, compared to $3.7 million in Q2 2025.
-
Cash Operating Expenses (excl. stock-based compensation):$3.7 million for Q2 2026, compared to $3.5 million in Q2 2025.
-
Expense Increase:$0.2 million increase in Q2 2026, driven by higher Niyad development expenses and initial market research activities.
-
Conditional Financing Tranches:Two tranches remain, totaling approximately $16 million in additional capital, expected to close around top-line data release.
Release Date: August 12, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Talphera Inc ( NASDAQ:TLPH ) has reached 75% enrollment in the NEPHRO CRRT study, with all final clinical sites activated and enrollment on track to complete later this year.
-
The 2026 KDIGO clinical practice guideline now references nafamostat as an acceptable regional anticoagulant, marking the first time it has been recommended in these guidelines and providing momentum for commercialization.
-
Updated market research indicates a larger market opportunity than initially estimated, with approximately 200,000 annual CRRT procedures expected in the US by 2027, a 21% increase from the prior estimate of 165,000.
-
Nafamostat is already standard medical practice in Japan and South Korea, where it is the most widely used anticoagulant during CRRT, with usage in about 80% of cases in Japan.
-
The company has sufficient cash, combined with future conditional financing tranches totaling approximately $16 million, to fund operations through at least a potential Niyad PMA approval expected in 2027.
-
Investigators have reported that nafamostat titration is straightforward, with 80-85% of patients reaching therapeutic range at the starting dose and maintaining it without multiple adjustments, unlike heparin.
-
The company has a strategic potential with CorMedix, which has a right of first negotiation for 60 days post data readout, potentially providing a commercialization pathway.
Negative Points
-
Talphera Inc ( NASDAQ:TLPH ) has a cash balance of only $17.1 million as of June 30, 2026, which may be insufficient if the conditional financing tranches do not close as expected.
-
The NEPHRO CRRT study is still blinded, and the company has not yet reported top-line data, leaving uncertainty about the trial's final results.
-
The KDIGO guideline currently positions nafamostat as an alternative to citrate, not a first-line therapy, which may limit initial adoption in the US where citrate is preferred in some institutions.
-
The company plans to hire only a couple of employees for pre-launch activities after PMA submission, which may be insufficient for a full commercial rollout.
-
The PMA filing is expected in the first half of next year, but the timeline could be delayed if the FDA requires additional meetings or data, pushing back the potential launch.
-
The market opportunity is concentrated in about 70 institutions representing over 50% of procedures, making the company's success highly dependent on a small number of key accounts.
-
The company has not yet provided a detailed timeline for the final KDIGO guideline publication, which could be delayed and affect commercialization momentum.
Q & A Highlights
Q: As you gear up toward a potential commercial launch, when would we start to see strategic hires, and what might the rollout strategy look like, such as targeting centers of excellence or high-enrolling sites? A: Vincent Angotti (CEO) stated that while Talphera has a strategic option with CorMedix, which holds a right of first negotiation for 60 days post-data readout, the company is preparing for launch independently. Hiring is expected to begin after the PMA submission, targeted for the first half of next year, with a focus on medical education roles rather than a traditional sales force. The rollout will be highly targeted, as data suggests approximately 70 institutions account for over 50% of the estimated 200,000 annual CRRT procedures, emphasizing account managers, educators, and peer-to-peer training.
Q: Can you clarify the timeline from full enrollment to data collection, top-line readout, and the subsequent steps needed to submit the PMA? A: Raffi Asadorian (CFO) explained that top-line data is expected approximately four to five weeks after completing enrollment. Following that, the company may request an interim meeting with the FDA to ensure clarity, adding roughly another three months before the PMA filing, which would place the submission within the first half of next year.
Q: Are there any necessary activities between PMA approval and a full commercial launch? A: Vincent Angotti (CEO) indicated that the goal is to launch at the time of approval, with no significant delay anticipated. Pre-launch activities, including market conditioning and medical education, are planned to coincide with the PMA submission to ensure readiness for an immediate launch upon approval.
Q: Have you received any notable feedback from the nephrologist principal investigators regarding the trial, and are there any insights into how they might use nafamostat if approved? A: Dr. Shakil Aslam (CMO) reported that the study is proceeding without surprises, with monitoring described as straightforward, simple, and predictable. The first independent Data Safety Monitoring meeting identified no risks or new findings. Many clinicians currently using or considering citrate have expressed they would prefer to wait for nafamostat, as it is simpler to use and requires no special training, with some indicating they would shift from using other agents as a second-line therapy to nafamostat as a proactive first-line therapy.
Q: Do you have any blinded insight into the titration happening in the NEPHRO CRRT trial, and is it tracking in line with expectations? A: Dr. Shakil Aslam (CMO) shared that while the study is blinded, the titration is behaving as expected. Most patients are titrated below half of the maximum allowed dose, with roughly 80-85% achieving therapeutic range at the starting dose and nearly 100% within half an hour. Patients often remain at the same dose for up to a week without needing retitration, a significant advantage over heparin, which often requires frequent adjustments.
Q: Regarding the KDIGO guidelines, is the recommendation for nafamostat based on ex-US usage, and does it differ from how you envision it being used in the US? A: Dr. Shakil Aslam (CMO) clarified that the draft guideline positions nafamostat as an alternative to citrate when citrate is contraindicated or unavailable. Since approximately 75% of US institutions do not have citrate available, this represents a substantial market opportunity. Even among the 25% that use citrate, its complexity and labor-intensive nature create a desire to switch to a simpler agent like nafamostat. In Japan and South Korea, where citrate is rarely used, nafamostat is already the first-line agent.
Q: What are the next steps for the KDIGO guidelines to become final, and how quickly are they typically adopted by US institutions? A: Dr. Shakil Aslam (CMO) estimated the final guidelines could be published within three to six months following the close of the public comment period in May. Adoption in the US is variable, but the inclusion of nafamostat validates its safety and efficacy and provides institutional stakeholders with a strong rationale to develop their own protocols, making it easier to adopt the recommendation.
Q: Can you provide any further details on the upcoming investor and analyst event? A: Raffi Asadorian (CFO) stated that the event will focus on the market opportunity and commercial approach, providing details on updated market research. Vincent Angotti (CEO) added that the research includes data on market sizing, growth rates, and stratification by disease states like sepsis, along with primary research from over 30 physicians and qualitative feedback from nurses on the burden of current anticoagulation methods. The synthesis of this data will inform launch mechanisms and be shared at the event.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
